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Abstract 
Multiple myeloma is a plasma cell malignancy that causes debilitating bone disease and 
fractures, in which TGFく plays a central role. Current treatments do not repair existing 
damage and fractures remain a common occurrence. We developed a novel low tumour phase 
murine model mimicking the plateau phase in patients, as we hypothesized this would be an 
ideal time to treat with a bone anabolic. Using in vivo microCT we show substantial and rapid 
bone lesion repair (and prevention) driven by SD-208 (TGFく receptor I kinase inhibitor) and 
chemotherapy (bortezomib and lenalidomide) in mice with human U266-GFP-luc myeloma. 
We discovered that lesion repair occurred via an intramembranous fracture repair-like 
mechanism and that SD-208 enhanced collagen matrix maturation to significantly improve 
fracture resistance. Lesion healing was associated with VEGFA expression in woven bone, 
reduced osteocyte-derived PTHrP, increased osteoblasts, decreased osteoclasts and lower 
serum TRACP-5b. SD-208 also completely prevented bone lesion development mice with 
aggressive JJN3 tumors, and was more effective than an anti-TGFく neutralizing antibody 
(1D11). We also discovered that SD-208 promoted osteoblastic differentiation (and overcame 
the TGFく-induced block in osteoblastogenesis) in myeloma patient bone marrow stromal 
cells in vitro, comparable to normal donors. The improved bone quality and fracture-
resistance with SD-208 provides incentive for clinical translation to improve myeloma patient 
quality of life by reducing fracture risk and fatality. 
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Introduction 
Multiple myeloma is a plasma cell neoplasm that is incurable for most patients. Myeloma is 
the second most common hematological malignancy and the incidence has risen by 66% 
since the 1970s.(1,2) Virtually all patients (~90%) develop a destructive bone disease(3), due to 
disruption of bone remodeling.(4,5) Sixty percent of patients experience bone fractures(6), 
which increases fatality(7,8) and treatment costs.(9-11) Current treatments for myeloma bone 
disease are limited to anti-resorptives, which can prevent further bone loss but are ineffective 
at repairing bone. Bone lesions (67%) and bone pain (60%) are frequently present at 
diagnosis(12), hence incorporation of a bone anabolic into myeloma patient care would 
dramatically reduce the occurrence of bone fractures and benefit patients immensely. 
 
Transforming growth factor beta (TGFく) is central to development and progression of 
myeloma bone disease. TGFく levels are elevated due to release from myeloma cells(13,14), 
bone marrow stromal cells (BMSCs)(13) and from the bone matrix during resorption.(15) TGFく 
regulates osteoclast and osteoblast differentiation, resulting in increased bone resorption and 
reduced bone formation.(15,16) Inhibition of TGFく has both bone anabolic and anti-resorptive 
effects in non-tumour-bearing mice(17,18), leading to increased bone volume and improved 
bone quality.(19) Similarly, TGFく inhibition prevented development of myeloma bone 
disease(20-22), and repaired existing bone lesions if administered with the bisphosphonate 
zoledronic acid.(23) 
 
Until recently, healing of lytic lesions in myeloma patients was generally considered to only 
occur in rare instances. Myeloma cells induce epigenetic changes that represses the Runx2 
promoter in osteoblast progenitor cells, resulting in persistent repression of osteoblast 
differentiation which prevents formation of new bone.(24) However, recent observations 
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showed 43% of patients on total therapy 4 exhibited lesion remineralization.(25) Healing was 
in part attributed to the bone modulating effects of the proteasome inhibitor bortezomib 
(btz)(26) and immunomodulatory drug lenalidomide (len). Btz has direct bone anabolic and 
anti-resorptive activity in vitro(27-32) and in vivo(32-34) and improves bone outcomes for 
myeloma patients.(25,29,35-42) Similarly, len has exhibited anti-resorptive effects(43,44) and 
reduced bone resorption in patients.(44) Furthermore, btz/len treatment would facilitate 
recovery of the bone marrow microenvironment by reducing tumour and hence normalize 
bone remodeling.  
 
While it is promising that btz and len have positive effects on bone, myeloma patients 
continue to experience skeletal-related events despite receiving these treatments, and new 
therapies are needed. This must be driven by identification of bone anabolic agents (e.g. 
TGFく inhibitors) that can heal and not just prevent further bone disease, in a reliable, 
clinically representative in vivo model. Considering osteoblast differentiation is repressed in 
myeloma patients, it is also integral that the ability of potential bone anabolics to overcome 
differentiation suppression is confirmed in patient samples. After treatment with 
chemotherapy, myeloma patients frequently enter a ‘plateau phase’ of clinical stability where 
tumour burden is (usually) low. We hypothesized that the plateau phase is the ideal time for 
anabolic treatment to repair bone. 
 
Here, we developed a murine model of myeloma where combination chemotherapy using btz 
and len induces a low tumour phase that mimics the plateau phase observed clinically, and 
allows for repair of bone lesions. Using this model, we showed that the TGFくRI kinase 
inhibitor, SD-208, stimulated rapid maturation of the collagen matrix leading to enhanced 
intramembranous bone repair and improved fracture resistance, without the use of an anti-
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resorptive. This mechanism of bone lesion repair has never before been identified in 
myeloma bone disease. We also provide evidence for efficacy in myeloma patients through 
stimulation of osteoblast differentiation of patient BMSCs with SD-208. 
Methods 
Study approval 
All animal experiments were approved by the University of Sheffield Animal Ethics 
Committee and the UK Home Office (PPL 70/8799) in strict compliance with the Animal 
(Scientific Procedures) Act 1986.  Bone marrow aspirates were obtained from myeloma 
patients and healthy donors with written informed patient consent and approval from the 
South Sheffield Research Ethics Committee (REC reference 05/Q2305/96). 
 
In vivo myeloma studies 
Female, 8-week-old NOD scid gamma (NSG, NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice 
(Charles River Laboratories) were randomized into groups and injected i.v. with PBS (naïve) 
or 106 human JJN3 cells. After 1 week, JJN3-bearing mice (n=8) were treated 5 days/week 
for 2 weeks with 60 mg/kg(17) SD-208 (Selleck Chemicals) by oral gavage, 20 mg/kg(23) 1D11 
(anti-TGFく antibody; Bio-Techné) by i.p. injection or controls (Fig. 1A). All mice were 
sacrificed after 2 weeks of treatment. 
  
To identify the effect of chemotherapy and SD-208 on bone repair, a low tumour model was 
developed. Female, 9-week-old NSG mice were injected i.v. with 106 human U266-GFP-luc 
cells (Fig. 2A). Tumour burden was monitored weekly by bioluminescent imaging using an 
IVIS Lumina II (Caliper Life Sciences) and serum paraprotein was measured by human IgE 
ELISA (Thermo Fisher Scientific). At 8 weeks post-tumour inoculation (referred to as 0 
weeks post-treatment), tibiae were scanned with a VivaCT80 pre-clinical µCT scanner 
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(Scanco) to confirm development of bone lesions and mice were treated with vehicles or 
chemotherapy (btz + len) ± SD208 (Selleck Chemicals), and sacrificed after 2 weeks of 
treatment (n=7). Vehicle mice were sacrificed after 1 week due to effects of the tumour on 
animal welfare and a separate group receiving chemotherapy were treated until relapse (n=5). 
Btz (i.p.), len (oral gavage) and SD-208 dosing schedules are described in Fig. 2A. Flow 
cytometry was used to measure tumour burden using a FACSCalibur (BD Biosciences) and 
FlowJo 10 (Treestar). All mice were group housed in individual ventilated cages with a 12-
hour light/dark cycle and ad libitum access to food and water. Mouse numbers were 
calculated prospectively using G*Power software. Endpoint and in vivo analyses were 
blinded. 
 
Micro computed tomography analyses 
Bone structure and osteolytic disease was monitored in vivo at -1, 0, 1 and 2 weeks post-
treatment by in vivo µCT, as previously described.(23) Briefly, mice were anaesthetized by 
isoflurane inhalation and tibiae were scanned at 10.4 µm isotropic voxel size, 55 kV, 145 µA, 
200 ms integration time for a 360° scan with a 0.24° rotation step on a VivaCT80 (Scanco) 
and images were reconstructed with Scanco software. Image registration was performed in 
DataViewer (1.5.4.6). Ex vivo µCT was performed on the contralateral tibia, femur, calvaria 
and L2 and L3 vertebrae using a SkyScan 1272 µCT scanner (Bruker, Kontich, Belgium) at 
4.3 µm voxel size, 0.5 mm aluminium filter, 50 kV, 200 µA for a 180° scan with a 0.7° 
rotation step and image reconstruction was performed using Skyscan software NRecon 
(1.6.9.4). Trabecular analysis was performed using DataViewer (1.5.4.6) and CTAn (1.8.1.2) 
following standard guidelines.(45) Tibial and femoral trabecular bone was analyzed in a 1mm 
region with a 0.2 mm and 0.4 mm distal offset from the growth plate, respectively. The 
region analyzed for vertebral (L2 and L3) trabecular bone was a 400 µm offset from the point 
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of 50% trabecular bone and 50% endplate on both ends of the vertebrae. Cortical osteolytic 
lesions of the proximal tibia to the tibial crest were measured using Osteolytica v1.9(46), using 
a minimum lesion size of 20,000 µm2. 3D models were created using Drishti software (v. 1.1, 
ANU Vizlab, Australia) and ParaView 5.4.1 software (New York, USA). 
Histomorphometry, immunohistochemistry and bone turnover markers 
Tibiae were fixed in 10% formalin for 24 hours then stored in 70% ethanol. One tibia from 
each mouse was decalcified, embedded in paraffin and 3 µm longitudinal sections were 
stained for tartrate-resistant acid phosphatase (TRAP), as previously described.(47) 
Histomorphometric analysis of osteoclast and osteoblast numbers and surfaces on 
endocortical bone were measured using Osteomeasure (OsteoMetrics, Atlanta, GA, USA) 
using standard guidelines.(48) Immunohistochemistry was performed on paraffin-embedded 
tibial sections using a rabbit anti-PTHrP (R87) antibody(49) (1:5000) specific to the amino 
terminus of PTHrP (1-34) or rabbit anti-VEGFA antibody (ab46154 1:1000, Abcam, 
Cambridge, UK) as described previously.(49,50) Contralateral tibiae were embedded in LR 
White medium resin (TAAB Laboratories, Aldermaston, UK) and 10 µm sections were used 
for dynamic histomorphometry analysis of alizarin/calcein labels.(47) Serum bone turnover 
markers TRAP5b (Oxford Biosystems, Oxford, UK) and P1NP (Immuno Diagnostic 
Systems, Tyne & Wear, UK) were measured by ELISA. 
 
Bone material characteristics 
Raman spectroscopy was performed on a XploRA Plus system with a 532 nm air-cooled Ar+ 
laser source (Horiba Scientific, Kyoto, Japan). Resin-embedded tibia were cut longitudinally 
into 10 µm sections and dried onto charged microscope slides. Spectra were obtained from 3 
evenly-spaced positions within the medial cortical bone (termed endocortical, middle and 
periosteal) across a 400 cm-1 to 1800 cm-1 spectral range.(51) All spectra are an average of 100 
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consecutive spectra, with a 10 second exposure, 5 mW laser power using a 100X objective. A 
least squares regression algorithm was used to fit the data with a polynomial function to 
remove background fluorescence. Data were normalized to the primary phosphate peak and 
smoothed by adjacent-averaging using OriginPro 2018b b9.5.5.409 (OriginLab Corporation, 
Northampton, MA, USA). Band fitting for the primary phosphate (1࢜PO4, ~960 cm-1), 
carbonate (CO3, ~1070 cm
-1) and amide I (~1610 cm-1 to ~1690 cm-1) bands were performed 
by fitting Gaussian functions. Amide I sub-peak analysis was performed by fitting 4 peaks at 
~1610 cm-1, 1638 cm-1, 1668 cm-1 and 1692 cm-1 using least squares regression, as previously 
identified.(52) An additional overlapping peak was included at 1601 cm-1 in the deconvolution. 
Mineral crystallinity was measured as the inverse of the full width at half maximum of the 1࢜PO4 band. Relative peak integral areas were used to calculate the mineral to matrix ratio 
 1PO4) and amide I sub-peak ratios࢜:1PO4:amide I), carbonate to phosphate ratio (CO3࢜)
(1668/1610, 1668/1638, 1668/1692 cm-1). 
 
Bone mechanical testing 
Femurs and vertebrae (L3 and L4) were fixed in 10% formalin for 24 hours then stored in 
70% ethanol prior to 3-point bending and compression testing, respectively. Three-point 
bending was performed on a Bose ElectroForce 3200 test instrument with a 450 N load cell, 
as previously described.(53) Femurs were placed on two rounded supports 6 mm apart, with 
load applied anteroposteriorly to the midshaft. A 0.5 N preload was applied, followed by a 
0.25 N/sec constant force until failure. The force-displacement curve was used to obtain 
ultimate force (N) given by the curve peak, and stiffness (n/mm) given by the gradient of the 
linear region of the curve. 
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Vertebral compression testing was performed on an Instron 5543 load frame with a 500 N 
load cell and Bluehills2 software (Instron, Norwood, MS, USA).(54) As the vertebral 
processes reduce sample stability during compression testing, processes were removed from 
L4 vertebrae prior to testing using a dental drill, whereas L3 vertebrae were kept intact. 
Vertebrae were glued to the mount with cyano-acrylate glue and compressed at a constant 
rate of 0.03 mm/s and a 20 Hz sample rate until 1 mm displacement. The force-displacement 
curve was used to obtain the ultimate force (N). 
 
Osteogenic differentiation of patient bone marrow stromal cells  
CD138- BMSCs were purified from bone marrow aspirates using CD138 MicroBeads 
(MACS Miltenyl Biotec). BMSCs were cultured in osteogenic media (gMEM with Glutamax 
supplemented with 10% (v/v) FCS, 100 µg/ml Streptomycin, 100 U/ml Penicillin, 0.01 mM 
dexamethasone, 200 µM ascorbate and 10 mM く-glycerophosphate)(55) supplemented with 5 
ng/ml recombinant TGFく (rTGFく), 1 µM SD-208, rTGFく + SD-208 or vehicles. Osteoblast 
formation was assessed by gene expression and alkaline phosphatase (ALP) activity.(55) 
 
Gene expression analyses 
Total RNA was isolated from human BMSCs or mouse bone marrow using a ReliaPrep RNA 
Cell MiniPrep System (Promega, Madison, WI, USA) and cDNA synthesized using a High-
Capacity RNA-to-cDNA Kit (Thermo Fisher Scientific). qPCR was performed using primers 
specifically targeting either mouse or human genes or TaqMan Gene Expression Assays 
(Supplemental Table I) with TaqMan Universal Master Mix II (Thermo Fisher Scientific) or 
SYBR Green Master Mix (Thermo Fisher Scientific) and 5 pmol of primers and detected 
with an ABI Prism 7900HT and SDS 2.1 software (Applied Biosystems, Foster City, CA, 
USA). 
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Statistical analysis 
All data are presented as mean±SD. Statistical analysis was performed in Prism 7 (GraphPad) 
using an unpaired two-tailed Student’s t test, one-way ANOVA or two-way ANOVA with 
Tukey’s multiple comparisons test.  
 
Data sharing statement 
The data generated during this study are available from the corresponding author 
(a.c.green@sheffield.ac.uk) upon reasonable request. 
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Results 
SD-208 prevents myeloma bone disease 
We previously reported prevention and repair of myeloma bone lesions with an anti-TGFく 
antibody, 1D11, in combination with zoledronic acid but without chemotherapy.(23) 
Numerous small molecule inhibitors of TGFく signaling are in clinical trials for other 
cancers(56) and SD-208 had a bone anabolic effect in naïve mice.(17) Thus, we investigated the 
efficacy of SD-208 (a TGFくRI kinase inhibitor) in treating myeloma bone disease using the 
aggressive JJN3 human xenograft model (Fig. 1A). Tibial trabecular bone volume and 
trabecular number were significantly lower in JJN3-bearing control mice compared to naïve 
mice (Fig. 1B-C). SD-208 or 1D11-treated mice had significantly higher trabecular bone 
volume and number compared to JJN3 controls (Fig. 1B-C). Trabecular thickness was 
comparable between all groups (Fig. 1D). The total lesion area in the proximal tibia was 
highest in the vehicle group (6.3±2.8%) and somewhat lower with 1D11 treatment 
(4.3±2.4%), whereas SD-208-treated mice had significantly lower lesion area (1.4±1%) 
compared to both control and 1D11-treated JJN3 mice, appearing similar to naïve mice 
(0.26±0.3%; Fig. 1E, H-K). This corresponded with significantly fewer lesions following SD-
208 treatment compared to control and 1D11-treated mice (Fig. 1F), but no change to average 
lesion size (Fig. 1G). This indicates that development of myeloma bone disease was 
substantially impaired with SD-208 treatment, which was more effective than 1D11 
treatment. Endocortical osteoblasts and osteoclasts were unaltered by SD-208 or 1D11 
treatment at endpoint (Fig. 1L-O), indicating that the effects of SD-208/1D11 at the cellular 
level must have been occurring at earlier timepoints to reflect the improved bone architecture 
at endpoint. 
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Bortezomib and lenalidomide induce a low tumour phase in U266-GFP-luc-bearing 
mice 
To develop a low tumour phase model that mimics the plateau phase observed clinically, Btz 
chemosensitivity of JJN3-GFP-luc, OPM2-GFP-luc and U266-GFP-luc cells was tested in 
vitro and in vivo (Supplemental Information and Supplemental Fig.1). Btz reduced the 
number of viable cells compared to the vehicle for all cell lines in vitro (Supplemental Fig.1). 
In vivo, btz treatment was the most effective at reducing tumour in the U266-GFP-luc mouse 
xenograft model, whereas no effect was observed in OPM2-GFP-luc-bearing mice and 
minimal effect was observed in JJN3-GFP-luc mice (Supplemental Fig. 1). Therefore, the 
U266-GFP-luc model was selected for further optimization with combined btz and len 
chemotherapy (Supplemental Fig. 2) to establish a low tumour phase model (Fig. 2A), 
mimicking the plateau phase. Btz+len administration at late-stage disease reduced tumour 
after 1 week by bioluminescent imaging in hindlimbs (~50 fold), vertebrae (~10 fold) and 
calvaria (~1000 fold) and serum paraprotein (Fig. 2B-G). This corresponded to >99% 
reduction bone marrow tumour burden by flow cytometry compared to vehicle (Fig. 2H). 
Tumour burden remained persistently low for 5-6 weeks prior to relapse (Fig. 2B-G). SD-208 
did not affect tumour burden by bioluminescent imaging, serum paraprotein or flow 
cytometry (Supplemental Fig. 3). 
 
SD-208 enhances bone lesion repair in combination with chemotherapy 
In the low tumour model, we performed in vivo µCT of tibiae prior to treatment (week 0) and 
after 1 and 2 weeks of chemotherapy with or without (±) SD-208. Lesions in vehicle-treated 
mice were unaltered or increased in size by week 1 (+18%; Fig. 3). Mice treated with 
chemotherapy exhibited similar bone lesion area and number after 1 week, but after 2 weeks 
lesion area was reduced by 52%, indicating partial lesion repair (Fig. 3A-C). Three-
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dimensional reconstructions showed thin bridging of holes in chemotherapy-treated mice 
(Fig. 3A-B). In comparison, after only 1 week, SD-208 + chemotherapy reduced total lesion 
area by 21% compared to vehicle (Fig. 3C). After 2 weeks, total lesion area was reduced by 
76%, showing significant improvement over mice treated with chemotherapy alone (Fig. 3C), 
with repair on all surfaces of the proximal tibia (Video 1). In mice treated with btz+len±SD-
208, lesion size and number were lower after 2 weeks (Fig. 3D-E). This was most 
pronounced with SD-208 treatment, with a 57% reduction in average lesion size and 49% 
reduction in lesion number, indicating lesions were smaller and nearly half were completely 
healed with SD-208 treatment. In vivo µCT monitoring of bone over successive timepoints 
identified that repair occurred from the marrow cavity out towards the bone exterior. New 
bone bridged perforating lesions at the endocortical surface, but lesions remained visible on 
the external surface as craters (Fig. 3A). Furthermore, the new bone formed between week 0 
and 1 in SD-208-treated mice was generally less dense bone (red-yellow) that was then 
replaced by more dense bone (yellow-blue) by week 2 (Fig. 3B). Despite the presence of 
tumour in calvaria, bone lesions were not present (Supplemental Fig. 4A-C). 
 
SD-208 increases trabecular bone volume in long bones 
Myeloma also causes a loss of trabecular bone, thus we investigated changes in trabecular 
bone by µCT for in vivo scanned tibiae, and bones isolated ex vivo including the contralateral 
tibia, femur and lumbar vertebrae (L2 and L3). There was a significant increase in trabecular 
bone volume in mice treated with btz+len+SD-208 compared to btz+len after 2 weeks in vivo 
(Fig. 4A). This was accompanied by an increase in trabecular number, with unaltered 
trabecular thickness or trabecular spacing (Fig. 4B-D). Ex vivo, there was also an increase in 
trabecular bone volume in the contralateral tibia by 60% (Fig. 4E) and femur by 74% (Fig. 
4J). Trabecular number increased and trabecular thickness was unchanged with btz+len+SD-
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208 treatment compared to vehicle in the contralateral tibia (Fig. 4F-G) and femur (Fig. 4K-
L). Trabecular separation was lower in mice treated with btz+len±SD-208 compared to 
vehicle-treated mice (Fig. 4H&M). In comparison, changes to vertebral trabecular bone were 
less pronounced and SD-208 provided no significant benefit beyond chemotherapy 
(Supplemental Fig. 4D-K). Thus, 2 weeks of SD-208 improved long bone trabecular bone 
architecture, but minimal benefit occurred in lumbar vertebrae. 
 
Bone remodeling is re-established during the low tumour phase and bones heal via 
intramembranous repair 
To identify the bone repair mechanism, we investigated changes to bone remodeling and 
myeloma bone disease regulators at endpoint. Histomorphometry revealed abundant TRAP+ 
osteoclasts on endocortical bone surfaces in vehicle mouse tibiae (Fig. 5A), which was 
noticeably diminished with btz+len±SD-208 treatment (Fig. 5B&C). Furthermore, 
btz+len±SD-208 treatment stimulated formation of woven bone along endocortical surfaces, 
which was particularly noticeable in regions with lytic lesions (Fig. 5B&C inset). The 
bridging of cortical lesions with woven bone mimics the repair mechanism reported in 
fracture repair models (e.g. drill-hole models(57)), suggesting myeloma bone lesions similarly 
heal by intramembranous bone repair. Histomorphometry also found that endocortical 
osteoclasts were reduced whereas osteoblasts were increased in mice treated with 
btz+len±SD-208 compared to vehicle (Fig. 5D-G). There was no difference between btz+len 
and btz+len+SD-208-treated mice, although this may have occurred at earlier timepoints (i.e. 
during repair) as lesions were already healed in the chemotherapy + SD-208 group at 
endpoint. The reduction in osteoclasts was supported by lower serum TRACP5b (Fig. 5H), 
indicating decreased resorption in mice administered btz+len±SD-208. Serum P1NP (bone 
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formation biomarker) was unchanged (Fig. 5I), indicating a change in total body bone 
formation was not detectable. 
 
Myeloma cells secrete or stimulate the microenvironment to express factors that cause 
myeloma bone disease.(4) We investigated expression of some myeloma bone disease genes 
by human U266-GFP-luc myeloma cells and mouse microenvironment cells isolated from 
femoral bone marrow. In vehicle-treated mice there was expression of human U266-derived 
TGFB1, DKK1, IL6, PTHLH, MET, TNF, CCL3, and FZB but not TNFSF11 (Fig. 5J). 
Consistent with McDonald et al.(58), we found SOST was not expressed by myeloma cells 
(Fig. 5J). None of the genes (including human GAPDH) were detected in bone marrow from 
btz+len±SD-208-treated mice, indicating tumour reduction prevented further production of 
bone disease-promoting factors. Furthermore, bone marrow expression of murine Tnfsf11 
(encoding RANKL) and Tnfrsf11b (encoding osteoprotegerin), commonly aberrant in 
myeloma, were unaltered (Supplemental Fig. 5A&B). Given osteocytes are the primary 
source of RANKL(59), it is still possible that RANKL signaling was altered. 
 
TGFく stimulates microenvironment expression of genes involved in tumorigenesis and bone 
disease in myeloma, including Il6, Vegfa, Mcp1(60), Pthlh (encoding PTHrP)(61) and Thbs1.(20) 
Thsp1, Mcp1 and Il6 expression in bone marrow was comparable between all treatment 
groups (Supplemental Fig. 5C-E). Vegfa expression was higher and Pthlh was lower in mice 
treated with chemotherapy ± SD-208 compared to vehicle mice (Fig. 6A&B).  
 
To identify the source of PTHrP within the microenvironment we performed 
immunohistochemistry. In vehicle mice, U266-GFP-luc myeloma cells and 86% of bone-
embedded osteocytes stained positive for PTHrP (Fig. 6C&D). In comparison, there was no 
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PTHrP expression in the bone marrow or osteocytes in mice treated with btz+len±SD-208 
(Fig. 6E&F). This indicates that chemotherapy inhibited expression of PTHrP by osteocytes, 
likely by reducing tumour burden. While non-tumour bearing (naïve) mice were not included 
in this study, we stained sections from age- and sex-matched mice from a previous study, 
finding that 58.8% ± 7.1% of osteocytes were PTHrP positive. Together, this identified that 
tumour cells increase expression of PTHrP levels in the bone marrow, not only from tumour-
derived production of PTHrP but also by stimulating expression in the microenvironment. 
Furthermore, considering chemotherapy ablated osteocyte PTHrP expression, this is not only 
reflective of reduced tumour, it also suggests bortezomib or lenalidomide may also reduce 
osteocytic PTHrP mechanism irrespective of tumour. 
 
VEGFA levels would be expected to decrease in response to TGFく inhibition(60) or 
chemotherapy(62), suggesting a different cause for the increase in Vegfa. VEGFA is a critical 
mediator of intramembranous facture repair(63,64), as such Vegfa would help facilitate lesion 
healing. Indeed, VEGFA immunohistochemistry (Fig. 6G-I) revealed VEGFA expression 
within the woven bone in mice treated with chemotherapy ± SD-208 (Fig. 6H&I). VEGFA 
was also expressed in the periosteum (Fig. 6G-I), tumour bone marrow (Fig. 6G) and 
megakaryocytes (Fig. 6H&I inset). 
 
 
SD-208 enhances femoral fracture resistance and collagen maturation 
Fractures are a common repercussion of myeloma bone disease that increase morbidity and 
fatality. To determine whether SD-208 improved fracture resistance, mechanical properties 
were assessed by femoral 3-point bending and vertebral compression. In femurs, the ultimate 
force (maximum load required to break the bone) and stiffness were increased in 
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btz+len+SD-208 compared to vehicle-treated mice but not chemotherapy alone (Fig. 7A&B). 
Btz+len significantly increased the ultimate force for L3 and L4 vertebrae, but no additional 
benefit was observed with SD-208 treatment (Fig. 7C&D). Prior to compression, L4 
vertebrae had their processes removed whereas L3 vertebrae were kept intact; this did not 
affect the trend between groups, however the force to failure in the vehicle groups was higher 
in L3 (40.75 N ± 11.28 N) compared to L4 (31.48 N ± 6.35 N). 
 
MicroCT revealed changes to bone structure, although as material composition and 
organization can also influence bone strength we performed Raman spectroscopy. MicroCT 
and histology analysis indicated that cortical bone lesions were healing from the endocortical 
surface out towards the periosteal surface. Raman spectra were collected from 3 regions in 
the cortical bone where lesions were undergoing repair: close to the endocortical surface, in 
the middle of the cortical bone and close to the periosteal surface (Fig. 7E&F). 
Mineralization (mineral-to-matrix ratio) and type B carbonate substitution (carbonate to 
phosphate ratio) were unchanged (Fig. 7H&I) and mineral crystallinity was the same for each 
sample (data not shown). Sub-peak analysis of the amide I band (Fig. 7G) was used to 
determine the effect of chemotherapy ± SD-208 on collagen cross-linking, as a surrogate 
measurement of matrix maturity. As bone matures, collagen fibrils undergo a series of cross-
linking reactions where immature divalent cross-links form, some of which then convert to 
mature trivalent cross-links.(65) This conversion is associated with an increase in the ~1668 
cm-1 to ~1692 cm-1 sub-peak ratio.(65) In the region close to the periosteal surface, the 
1668:1692 ratio was significantly higher in mice treated with btz+len+SD-208 compared to 
chemotherapy alone (Fig. 7J), indicating enhanced matrix maturation with SD-208 treatment. 
The improvements to bone architecture and collagen cross-linking with SD-208 treatment 
both contribute to making stronger, more fracture-resistant bone.  
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SD-208 promotes myeloma patient and normal osteoblast formation in vitro 
To determine the effect of TGFく inhibition on osteoblast formation, BMSCs isolated from 
normal donor (N-BMSCs) and myeloma patient (MM-BMSCs) samples were cultured in 
osteogenic media with recombinant TGFく (rTGFく) and/or SD-208. N-BMSCs and MM-
BMSCs treated with SD-208 had significantly higher ALP activity compared to rTGFく-
treated BMSCs at all timepoints (Fig. 8A&B). At day 7 and 10, SD-208-treated BMSCs had 
higher ALP activity than vehicle-treated N-BMSCs and MM-BMSCs (Fig. 8A&B). BMSCs 
treated with rTGFく+SD-208 had significantly higher ALP activity at day 7 and 10 compared 
to rTGFく alone, with levels comparable to vehicle-treated BMSCs (Fig. 8A&B). No 
significant differences were observed in osteoblastic gene expression between treatment 
groups (Fig. 8C-L), likely due to substantial variation between patient cells. However, there 
was a trend towards increased expression of the early osteoblastic gene SP7 (encoding 
Osterix) with rTGFく treatment (Fig. 8D&I) and increased expression of later genes ALPL and 
PTH1R with SD-208 treatment (Fig. 8E&F, J&K) in both N-BMSCs and MM-BMSCs. 
Furthermore, BGLAP (encoding Osteocalcin) expressed by mature osteoblasts was only 
detectable in BMSCs treated with SD-208, and in vehicle-treated MM-BMSCs (but not N-
BMSCs) (Fig. 8G&L). This indicates that SD-208 treatment blocks the inhibitory effect of 
rTGFく on osteoblast differentiation, while preventing earlier progenitor cell 
proliferation.(15,16) The data also suggest SD-208 treatment alone can promote osteogenic 
differentiation of N-BMSCs and MM-BMSCs compared to vehicle without rTGFく 
supplementation.  
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Discussion 
Virtually all myeloma patients develop bone disease, which is painful, debilitating and 
increases fractures and mortality.(3,6-8) New bone-targeted therapies that heal bone and 
increase strength are needed to improve patient quality of life, especially given overall
survival is increasing. We developed a novel low tumour xenograft model of myeloma to 
mimic the plateau phase by treating with first-line chemotherapeutics btz and len. SD-208 
treatment during the low tumour phase induced rapid intramembranous healing of bone 
disease by modulating collagen maturation, PTHrP and Vegfa. We also identified for the first 
time improved fracture resistance following repair of myeloma bone disease in vivo. 
Furthermore, we discovered that SD-208 enhances formation of osteoblasts from MM-
BMSCs, providing evidence of efficacy in patients. 
 
SD-208 combined with chemotherapy induced rapid healing of myeloma bone disease in 
U266-GFP-luc-bearing mice. After only 2 weeks, all mice treated with SD-208 plus 
chemotherapy had substantial repair of bone lesions. Half of the lesions were completely 
repaired, and remaining lesions were reduced in size by nearly 60% with SD-208 treatment + 
chemotherapy, which was substantially more effective than chemotherapy alone. Similarly, 
SD-208 increased trabecular bone volume in long bones, supporting previous studies in naïve 
mice(17) and with 1D11 in myeloma-bearing (JJN3, U266 and 5TGM1) mice.(21,23) 
Chemotherapy-treated mice also exhibited lesion repair, reflecting recent observations in 
patients.(25,39-41) However, chemotherapy-driven repair was less effective than when 
combined with SD-208. Importantly, by combining SD-208 with chemotherapy we observed 
more effective repair within 2 weeks, even without anti-resorptive therapy and despite 
administration at a very late disease stage, differing from previous studies treating for longer 
periods or prior to tumour development.(21,23) Furthermore, we identified that chemotherapy 
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alleviated not only the tumour-derived pro-osteoclastic signals, but also eliminated 
expression of pro-osteoclastic PTHrP in osteocytes, which were previously an unidentified 
source of PTHrP in myeloma. Given TGFく stimulates PTHrP expression(61) we would expect 
SD-208 to also inhibit PTHrP expression, but given the complete elimination of osteocytic 
PTHrP in mice receiving chemotherapy alone, any further benefit with SD-208 was not 
measurable. Thus, effective reduction of tumour can remove the osteoclastic drive from the 
microenvironment, suggesting conventional anti-resorptives may not always be necessary in 
vivo. The bone effects of SD-208 were not limited to the U266-GFP-luc model, as myeloma 
bone disease was also reduced with preventative treatment of JJN3-bearing mice and was 
more effective than 1D11 at preventing bone lesions. Thus, SD-208 effectively prevented 
myeloma bone disease and when administered with chemotherapy rapidly repaired bone 
lesions across multiple murine models, and was more effective than 1D11.(21,23) 
 
Reports of osteolytic lesions healing are increasing, yet the mechanism of repair is unknown 
and it is unclear why only some patients exhibit repair. We identified that healing of 
myeloma bone disease occurred through deposition of ‘trabecular-like’ woven bone along the 
endocortical surface that bridged lesions, without evidence of a cartilage callus. This suggests 
lesion repair occurred via process reminiscent of intramembranous fracture repair (as in 
drill-hole repair models(57)) rather than typical cortical remodeling or endochondral 
ossification. Supportive of this, we observed an increase in Vegfa, which plays a critical role 
in coupling of angiogenesis and osteogenesis during intramembranous repair.(63,64) In 
myeloma patients, healing of bone lesions has been observed in flat bones of the pelvis(25), 
which form via intramembranous ossification. As such, it is plausible that this could be the 
mechanism of repair in patients. Furthermore, it reinforces that the treatment for myeloma 
bone disease can be improved through pharmacological routes and that this has the potential 
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to make a substantial difference to patient morbidity and mortality, alleviating the reliance on 
anti-resorptive therapy, radiotherapy and invasive orthopedic approaches. 
 
One area of concern in healing of myeloma bone disease r lat s to the quality and integrity of 
the new bone. In patients, µCT has provided evidence of mineralized tissue in place of 
previous lesions, which appears to resemble bone.(25) A novel finding from our study was that 
SD-208 does not affect mineralization during healing, but stimulates maturation of the 
collagen matrix. Changes in collagen cross-linking, without changes to mineral, in newly 
formed bone can determine mechanical integrity(66) and thus the increase in matrix maturity 
with SD-208 may contribute to the improved mechanical strength. 
 
A major cause of morbidity in myeloma patients is pain and mobility loss resulting from 
fractures caused by myeloma bone disease. SD-208 treatment improved bone architecture 
and material properties in long bones, leading to enhanced femoral fracture resistance. 
Vertebral fracture resistance improved significantly in response to chemotherapy. 
Considering the effect on vertebral bone volume was moderate, and only significant in L3 
vertebrae, it is likely that a reduction in cortical lesions may also be contributing to the 
improved fracture resistance. In comparison to long bones, no additional improvement in 
vertebrae was observed with SD-208, reflecting the less pronounced trabecular bone 
architectural changes. This contrasts to findings in naïve mice where SD-208 (60 mg/kg for 6 
weeks) increased vertebral fracture resistance in males and increased bone formation in male 
(but not female) lumbar vertebrae.(17) Our studies used female mice, so it is possible that the 
effect of SD-208 in the vertebrae is less pronounced in females or requires a longer treatment 
duration. Furthermore, we observed an increase in ultimate force to failure with 
chemotherapy (34% in L3 and 45% in L4 vertebrae) after 2 weeks, whereas Mohammad et 
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al. observed a 27% increase after 6 weeks of SD-208 treatment(17), i dicating that in the 
vertebrae the strong anabolic effect in response to chemotherapy (either attributed to direct 
effects of bortezomib or to the reduction in tumour load) masks any anabolic effect from SD-
208. Site-specific effects similarly occur in response to PTH bone anabolic therapy in mice, 
with anabolic responses in lumbar vertebrae being slower (not observed until 7 weeks, 
compared to 3 weeks in long bones) and of smaller magnitude than in long bones.(67) 
Importantly, this is the first study to show improved fracture resistance with bone anabolic-
driven repair (rather than prevention) of myeloma bone disease. Many patients present with 
myeloma bone disease at diagnosis(12), thus the ability to improve bone strength by repairing 
bone is vital and has the potential to vastly improve patient quality of life and reduce the need 
for more extreme surgical interventions. 
 
The improved prevention of bone lesions with SD-208 over 1D11 in JJN3-bearing mice was 
somewhat surprising. However, this may explain why Nyman et al. did not observe improved 
fracture resistance when treating myeloma-bearing mice with 1D11±btz prior to lesion 
development(21), despite the fact that 1D11 improved fracture resistance in naïve mice.(19) 
TGFく signals by binding to TGFくRII, which phosphorylates and activates TGFくRI and 
downstream SMAD signaling. TGFく signaling is specific to TGFくRI(68), and would be 
targeted by both 1D11 and SD-208. The reason for the improved lesion prevention with SD-
208 compared to 1D11, cannot conclusively be identified in our study, but may be due to the 
differences in administration (i.e. dose, route) or the pharmacokinetics and 
pharmacodynamics of each drug. For instance, there may be additional benefits to bone with 
SD-208 due to off-target effects, as SD-208 also has a >25% inhibition of other kinases 
including AKT1-3, protein kinase C (i, さ and し isoforms), epidermal growth factor receptor, 
protein kinase D and mitogen-activated protein kinase-activated protein 2.(69,70) 
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Bone anabolics show great promise in healing myeloma bone disease. Prevention of lesion 
development has been observed with anti-TGFく therapies (1D11(21,23) and now SD-208), an 
anti-sclerostin antibody(58,71), an anti-DKK1 antibody(72) and a soluble decoy receptor for 
activin A(73) in vivo. Repair of bone lesions was observed with 1D11 in combination with 
zoledronic acid.(23) Here we show more rapid repair with SD-208 combined with btz and len, 
without the use of conventional anti-resorptives, in a novel U266-GFP-luc low tumour phase 
model. Our findings identify the bone anabolic and anti-resorptive actions of SD-208 have 
the potential to treat pre-existing myeloma bone lesions as well as prevent further bone 
disease, significantly enhancing the bone effects of first-line chemotherapeutics. This model 
was developed for improved clinical representation, and optimized in NSG 
immunocompromised mice bearing U266-GFP-luc tumors. This was based on a number of 
factors, most importantly being that 1) the U266 cells induce osteolytic disease and 2) the 
mice exhibited a prolonged low tumor phase after chemotherapy. The lack of a fully 
functioning immune system in NSG mice is a potential limitation to the low tumour model, 
however our findings are supported by Nyman and colleagues’ treatment of 
immunocompetent 5TGM1-bearing mice with 1D11.(21) Further, in accordance with previous 
studies(21,23), we did not observe any effect on the tumour with SD-208, supporting use as a 
bone anabolic in myeloma. 
 
The potential for SD-208 to stimulate osteoblastic differentiation was confirmed in myeloma 
patient BMSCs, and comparable to the response in healthy donor BMSCs. Promisingly, SD-
208 not only alleviated TGFく-induced repression of osteoblastic differentiation, but also 
promoted osteogenesis of MM-BMSCs and N-BMSCs without rTGFく supplementation. 
TGFく inhibitors have been reported to overcome the impaired osteoblast differentiation 
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caused by TGFく or myeloma conditioned medium in osteoblastic cell lines and primary 
murine BMSCs.(22,23) However, this is the first time that  TGFく inhibitor has been shown to 
promote osteoblast differentiation of MM-BMSCs. Thus, the ability of SD-208 to promote 
osteoblast formation suggests bone anabolic efficacy in humans and substantiates our 
findings in murine models. 
 
We have identified that he TGFくRI inhibitor, SD-208, enhances repair of myeloma bone 
disease when combined with first-line chemotherapeutics, btz and len. We found SD-208 
healed bone through a process similar to intramembranous fracture repair, stimulating faster 
matrix maturation to rapidly improve bone architecture and increase femoral fracture 
resistance. We also identified that myeloma patient BMSCs are capable of forming 
osteoblasts, and that this is enhanced by SD-208. Inhibitors of TGFく signaling, SD-208 and 
1D11, have now been consistently shown to prevent and repair bone disease in 
immunocompetent syngeneic (5TGM1) and immunodeficient xenograft (JJN3, U266) murine 
myeloma models. TGFく inhibition in combination with first-line chemotherapies has the 
potential to substantially benefit patient quality of life, survival and cost of treatment, by 
improving bone architecture and strength and hence reducing skeletal related events. 
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Figure 1: TGFく inhibition with SD-208 or 1D11 prevents osteolytic lesion development 
and loss of trabecular bone. (A) Schematic showing in vivo treatment schedule. NSG mice 
were inoculated with 106 JJN3 cells or PBS (naïve). After 1 week, mice were treated with 60 
mg/kg SD-208, 20 mg/kg 1D11 or controls 5 days/week for 2 weeks. Mice were then 
sacrificed for analysis of bone disease by ex vivo µCT and histomorphometry. MicroCT 
analysis of tibial (B) trabecular bone volume/tissue volume (BV/TV), (C) trabecular number 
(Tb.N), (D) trabecular thickness (Tb.Th), (E) osteolytic lesion area, (F) average lesion size 
and (G) lesion number. Representative reconstructed images are shown for (H) naïve, (I) 
JJN3 control-treated, (J) SD-208 and (K) 1D11 mice. Histomorphometry was performed on 
TRAP-stained, decalcified paraffin-embedded tibiae. Histomorphometric analysis of (L) 
osteoclast number/endocortical surface (N.Oc/Ec.S), (M) osteoclast surface/endocortical 
surface (Oc.S/Ec.S), (N) osteoblast number/endocortical surface (N.Ob/Ec.S) and (O) 
osteoblast surface/endocortical surface (Ob.S/Ec.S). Data are mean±SD (n=8 mice). # 
p=0.05, ## p=0.01, ### p=0.001, #### p=0.0001 (unpaired two-tailed Student’s t test 
between naïve and JJN3 controls) and *p=0.05, **p=0.01, ***p=0.001 and ****p=0.0001 
(one-way ANOVA with Tukey’s multiple comparisons test between JJN3 control, SD-208 
and 1D11 mice). 
 
Figure 2: Bortezomib and lenalidomide combined chemotherapy induces a low tumour 
phase when administered at late stage disease. (A) Schematic showing in vivo treatment 
schedule. NSG mice were inoculated with 106 U266-GFP-luc cells. After 8 weeks (when 
bone lesions were present), treatment was commenced (week 0). Vehicle mice were 
sacrificed after 1 week (*1, n=7 mice) due to effects of tumour, btz + len mice were 
sacrificed after 2 weeks (*2, n=7 mice) and after relapse (*3, n=5 mice) and btz+len+SD-208 
mice after 2 weeks (*4, n=7 mice). Bioluminescent imaging was performed weekly and in 
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vivo µCT was performed weekly from week 7. Bioluminescent quantification of tumour in 
the (B) hindlimbs, (C) vertebrae and (D) calvaria and the representative images show tumour 
burden in vehicle and btz+len treated mice imaged (E) anteriorly and (F) posteriorly. (G) 
Paraprotein (human IgE) was measured in mouse sera by ELISA. (H) The proportion of 
GFP+ tumour cells was assessed in femur-flushed bone marrow by flow cytometry. Data are 
mean±SD. ****p=0.0001 (unpaired two-tailed Student’s t test). 
 
Figure 3: SD-208 enhances lesion repair in combination with chemotherapy. 
Representative 3D reconstructed µCT images of tibia in the same mouse showing (A) 
osteolytic cortical bone lesions from week 0, 1 and 2 post-treatment (arrows indicate lesions 
that are worse (red), the same (yellow), show some repair (dark blue) or complete repair 
(blue) compared to week 0) and (B) transverse cross sections with density gradient coloring 
showing lesion repair and cortical thickening (white asterisk) in btz+len±SD-208 treated 
mice. Osteolytica was used to quantify (C) total lesion area, (D) average lesion size and (E) 
lesion number of the proximal tibia as % change from week 0. Data are mean±SD (=7 
mice). *p=0.05 (week 1; one-way ANOVA with Tukey’s multiple comparisons test and week 
2; unpaired two-tailed Student’s t test). 
 
Figure 4: SD-208 increases trabecular bone volume in combination with chemotherapy. 
Trabecular bone architecture was assessed by in vivo µCT of (A-D) one tibia (week 0, 1 and 
2 post-treatment) and ex vivo µCT of the (E-I) contralateral tibia and (J-M) femur at endpoint. 
MicroCT analysis of tibial and femoral (A, E, J) trabecular bone volume/tissue volume 
(BV/TV), (B, F, J) trabecular number (Tb.N), (C, G, L) trabecular thickness (Tb.Th) and (D, 
I, M) trabecular separation. Representative reconstructed images of trabecular bone are 
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shown for ex vivo scanned tibiae. Data are mean±SD (n=7 mice). *p=0.05, **p=0.01 and 
***p=0.001 (one-way ANOVA with Tukey’s multiple comparisons test). 
 
Figure 5: Chemotherapy reduces osteoclasts and bone resorption, increases osteoblasts 
and alters microenvironment expression of Vegfa and PTHrP. Histomorphometry of 
endocortical surfaces was performed on TRAP-stained, decalcified paraffin-embedded tibiae. 
Representative images of (A) vehicle, (B) btz+len and (C) btz+len+SD-208 treated mice 
show osteoclasts (red arrowheads), osteoblasts (blue arrowheads), bone marrow (BM) tumour 
(T)-BM) and the formation of woven bone (WB) on the endocortical surface of cortical bone 
(CB). Scale bars are 400 µm (proximal tibia) and 100 µm (inset). Histomorphometric 
analysis of (D) osteoclast number/endocortical surface (N.Oc/Ec.S), (E) osteoclast 
surface/endocortical surface (Oc.S/Ec.S), (F) osteoblast number/endocortical surface 
(N.Ob/Ec.S) and (G) osteoblast surface/endocortical surface (Ob.S/Ec.S). (H) TRACP5B and 
(I) P1NP levels were measured in mouse sera by ELISA. (J) mRNA expression of tumour-
derived factors that contribute to myeloma bone disease were measured in the bone marrow 
by qPCR using human-specific primers. Slides were scanned at 40X on a Pannoramic 250 
(3DHistech).  Data are mean±SD (n=7 mice). *p=0.05, **p=0.01, ***p=0.001 and 
****p=0.0001 (one-way ANOVA with Tukey’s multiple comparisons test). 
 
Figure 6: Chemotherapy reduces osteocytic PTHrP and VEGFA is expressed during 
bone healing. mRNA expression of microenvironment-derived (A) Vegfa and (B) Pthlh were 
measured in the bone marrow by qPCR using mouse-specific primers. PTHrP and VEGFA 
protein expression was identified by immunohistochemistry of decalcified paraffin-embedded 
tibiae. (C) The proportion of PTHrP+ osteocytes was determined for cortical bone. (D-F)
Representative images of sections stained for PTHrP for (D) vehicle, (E) btz+len and (F) 
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btz+len+SD-208 treated mice show PTHrP positive osteocytes (black arrowheads) and 
PTHrP negative osteocytes (white arrowheads), scale bar is 20 µm. (G-E) Representative 
images of sections stained for VEGFA for (G) vehicle, (H) btz+len and (I) btz+len+SD-208 
treated mice show VEGFA expression in woven bone (WB), the periosteum (Ps) and in 
megakaryocytes (grey arrowheads), scale bars are 400 µm, 200 µm (inset) and 100 µm 
(dotted line inset). Slides were scanned at 40X on a Pannoramic 250 (3DHistech).  Data are 
mean±SD (n=7 mice, for Pthlh n=4-7 due to insufficient mRNA for some mice). *p=0.05, 
***p=0.001 and ****p=0.0001 (one-way ANOVA with Tukey’s multiple comparisons test). 
 
Figure 7: SD-208 enhances matrix maturation and improves femoral fracture 
resistance. Three-point bending was performed on the femur to determine the (A) ultimate 
force to failure and (B) stiffness. Compression testing was performed on (C) L3 and (D) L4 
vertebrae to determine the ultimate force. (E) Raman spectroscopy was performed in 3 
regions of the cortical bone (yellow dots) referred to as endocortical (Ec), middle (Mid) and 
periosteal (Ps) in mice treated with vehicle, btz+len or btz+len+SD-208. (F) Example Raman 
spectrum showing the primary phosphate (1࢜PO4), carbonate (CO3) and amide I peaks. (G) 
Example sub-peak analysis of the amide I peak. Raman peak analysis of the (H) mineral to 
matrix ratio (1࢜PO4:amide I), (I) carbonate to phosphate ratio (CO3:1࢜PO4) and (J) matrix 
maturity ratio from amide I subpeak analysis (1668 cm-1:1692 cm-1). Data are mean±SD (-
Raman n=3 mice, mechanical loading n=4-7 mice). *p=0.05, **p=0.01, ***p=0.001 and 
****p=0.0001 (one-way ANOVA with Tukey’s multiple comparisons test). 
 
Figure 8: SD-208 promotes formation of alkaline phosphatase positive osteoblasts from 
normal and myeloma patient BMSCs.  Adherent CD138- BMSCs from normal donor (N-
BMSCs) and myeloma patient (MM-BMSCs) were cultured in osteogenic media containing 
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vehicles or recombinant TGFく (rTGFく) and/or SD-208. (A-B) After 3, 7 and 10 days cells 
were alkaline phosphatase (ALP) assays were performed on (A) N-BMSCs and (B) MM-
BMSCs. After 7 and 14 days qPCR of osteoblastic genes RUNX2, SP7, ALPL, PTH1R and 
BGLAP was performed on (C-G) N-BMSCs and (H-L) MM-BMSCs. ND = not detected. 
Data are mean±SD (n=3 independent patients) *p=0.05, **p=0.01, ***p=0.001 and 
****p=0.0001 (two-way ANOVA with Tukey’s multiple comparisons test). 
  
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d
 A
rt
ic
le
  
 
  
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d
 A
rt
ic
le
  
 
  
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d
 A
rt
ic
le
  
 
  
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d
 A
rt
ic
le
  
 
  
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d
 A
rt
ic
le
  
 
  
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d
 A
rt
ic
le
  
 
  
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d
 A
rt
ic
le
  
 
  
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d
 A
rt
ic
le
  
 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d
 A
rt
ic
le
